<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686881</url>
  </required_header>
  <id_info>
    <org_study_id>P04773</org_study_id>
    <secondary_id>JPC-05-356-30</secondary_id>
    <nct_id>NCT00686881</nct_id>
  </id_info>
  <brief_title>Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)</brief_title>
  <official_title>A Clinical Study of SCH 54031 as Monotherapy in IFN-treated Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy of peginterferon alfa-2b (PegIFN-2b)
      monotherapy administered at a dose of 0.5 ug/kg vs stronger neo minophagen C (SNMC) in
      participants with chronic hepatitis C (CHC) and liver fibrosis (Metavir fibrosis score of F2
      and F3) who were previously treated with interferon. The trial will evaluate the effect of
      treatment on the progression of liver fibrosis, liver inflammation, and liver function.
      Treatment will be administered for up to 156 weeks with a 4-week follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated due to low enrollment
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Change in Metavir Fibrosis Score</measure>
    <time_frame>Baseline and discontinuation of treatment (up to 156 weeks)</time_frame>
    <description>Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase (ALT) Normalization of &gt;16 Weeks Duration</measure>
    <time_frame>Week 24</time_frame>
    <description>The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Metavir Inflammation Score</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PegIFN-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SNMC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b (PegIFN-2b)</intervention_name>
    <description>PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks</description>
    <arm_group_label>PegIFN-2b</arm_group_label>
    <other_name>SCH 054031</other_name>
    <other_name>Pegylated interferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Stronger neo minophagen C (SNMC)</intervention_name>
    <description>SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .</description>
    <arm_group_label>SNMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis C previously treated with interferon

          -  At least 20 years of age

          -  Liver fibrosis score rated as F2 or F3 based on the result of liver biopsy at
             screening

          -  Female patients willing to use contraception

          -  Body weight from 35.0 kg to 110.0 kg (inclusive)

          -  Positive for hepatitis C virus ribonucleic acid (HCV-RNA) by qualitative assay

          -  Patients who meet the following laboratory criteria:

               -  Serum alanine aminotransferase (ALT) level: &gt;60 IU/L

               -  Neutrophil count: &gt;=1,200/mm^3

               -  Platelet count: &gt;=100,000/mm^3

               -  Serum potassium level: &gt;=3.5 mEq/L

        Exclusion Criteria:

          -  Patients who received interferon therapy within 90 days of Screening

          -  Patients who have received antiviral agents or antitumor agents, or immunomodulator
             therapy (including chronic glucocorticoids and radiotherapy) within 90 days of
             Screening (excluding local administration and topical use)

          -  Patients who have received other investigational drugs within 90 days of Screening

          -  Hepatitis B surface antigen (HBs)positive

          -  Antinuclear antibody titer of 1:320 or higher

          -  Creatinine level exceeding the upper limit of the reference range measured at
             screening test 2;

          -  Fasting blood glucose level of &gt;=126 mg/dL

          -  Patients on insulin therapy regardless of the fasting blood glucose level

          -  Patients who have a concurrent or past history of any of the following conditions:
             liver cirrhosis, liver failure, or liver carcinoma; hepatic encephalopathy, esophageal
             varices requiring treatment, or ascites; suicidal attempt or ideation; epileptic
             seizures requiring drug therapy; angina pectoris, heart failure, myocardial infarction
             or fatal arrhythmia; autoimmune disease (Hashimoto's disease [chronic thyroiditis],
             Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic
             purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma,
             etc.); malignant tumors (it is permitted to register patients with at least 5 years
             after cure).

          -  Patients who concurrently have any of the following conditions: liver disease such as
             autoimmune hepatitis, alcoholic liver injury, and drug-induced hepatitis; hemophilia;
             depression or schizophrenia which requires treatment; hypertension which cannot be
             controlled by drug therapy or arrhythmia which requires treatment, chronic pulmonary
             disease; abnormal thyroid function that cannot be controlled by drug therapy; organ
             transplants (other than corneal, hair transplant, etc.); aldosteronism, myopathy, or
             hypokalemia.

          -  Patients with a history of hypersensitivity to interferon preparations or biological
             products such as vaccines

          -  Patients with a history of hypersensitivity to monoammonium glycyrrhizinate, glycine,
             or L-cysteine monohydrochloride;

          -  Women who are pregnant or lactating, and women in whom pregnancy cannot be ruled out
             based on the result of serum human chorionic gonadotropin (HCG) measurement at
             Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>February 3, 2012</results_first_submitted>
  <results_first_submitted_qc>February 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2012</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Glycyrrhizic Acid</mesh_term>
    <mesh_term>Glycyrrhetinic Acid</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PegIFN-2b</title>
          <description>Participants receiving peginterferon alfa-2b (PegIFN-2b) at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
        </group>
        <group group_id="P2">
          <title>SNMC</title>
          <description>Participants receiving stronger neo minophagen C (SNMC) 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127">After randomization, 2 participants withdrew consent and did not receive study drug.</participants>
                <participants group_id="P2" count="134">After randomization, 6 participants withdrew consent and did not receive study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment-related adverse event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Onset of malignant tumor</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Circumstances of site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Irregular visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never received study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PegIFN-2b</title>
          <description>Participants receiving peginterferon alfa-2b (PegIFN-2b) at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
        </group>
        <group group_id="B2">
          <title>SNMC</title>
          <description>Participants receiving stronger neo minophagen C (SNMC) 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Of the 261 randomized participants, 253 received study drug; 1 of these participants in the SNMC Arm had no data available after initial treatment and is excluded from study analyses.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="9.5"/>
                    <measurement group_id="B2" value="60.7" spread="8.9"/>
                    <measurement group_id="B3" value="60.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Of the 261 randomized participants, 253 received study drug; 1 of these participants in the SNMC Arm had no data available after initial treatment and is excluded from study analyses.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Of the 261 randomized participants, 253 received study drug; 1 of these participants in the SNMC Arm had no data available after initial treatment and is excluded from study analyses.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change in Metavir Fibrosis Score</title>
        <description>Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).</description>
        <time_frame>Baseline and discontinuation of treatment (up to 156 weeks)</time_frame>
        <population>All treated participants excluding 2 participants on the PegIFN-2B arm and 1 participant on the SNMC arm for whom baseline data were non-evaluable or for whom no post-baseline data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIFN-2b</title>
            <description>Participants receiving peginterferon alfa-2b (PegIFN-2b) at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SNMC</title>
            <description>Participants receiving stronger neo minophagen C (SNMC) 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Metavir Fibrosis Score</title>
          <description>Metavir fibrosis score is a 5-point scale based on the amount of fibrosis in the liver, ranging from F0 (best, no fibrosis) to F4 (worst, cirrhosis).</description>
          <population>All treated participants excluding 2 participants on the PegIFN-2B arm and 1 participant on the SNMC arm for whom baseline data were non-evaluable or for whom no post-baseline data were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with ≥1grade lower score (improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with no change in score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with ≥1 grade higher score (worsened)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase (ALT) Normalization of &gt;16 Weeks Duration</title>
        <description>The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.</description>
        <time_frame>Week 24</time_frame>
        <population>All treated participants except 1 SNMC participant who had no available data after initial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIFN-2b</title>
            <description>Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SNMC</title>
            <description>Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase (ALT) Normalization of &gt;16 Weeks Duration</title>
          <description>The ALT was judged to have been normalized when the ALT level was 35 IU/L or below.</description>
          <population>All treated participants except 1 SNMC participant who had no available data after initial treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Metavir Inflammation Score</title>
        <description>Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>All treated participants excluding 3 participants on the PegIFN-2b arm and 1 participant on the SNMC arm for whom baseline data were non-evaluable or for whom no post-baseline data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIFN-2b</title>
            <description>Participants receiving peginterferon alfa-2b (PegIFN-2b) at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.</description>
          </group>
          <group group_id="O2">
            <title>SNMC</title>
            <description>Participants receiving stronger neo minophagen C (SNMC) 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Metavir Inflammation Score</title>
          <description>Metavir inflammation score is a 4-point scale based on the severity of inflammation in the liver, ranging from A0 (best, no activity) to A3 (worst, severe activity).</description>
          <population>All treated participants excluding 3 participants on the PegIFN-2b arm and 1 participant on the SNMC arm for whom baseline data were non-evaluable or for whom no post-baseline data were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with ≥1grade lower score (improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with no change in score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with ≥1grade higher score (worsened)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All treated participants except one SNMC participant who had no available data after initial treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>PegIFN-2b</title>
          <description>Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for
up to 156 weeks.</description>
        </group>
        <group group_id="E2">
          <title>SNMC</title>
          <description>Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up
to 156 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MENIERE'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>OVARIAN NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANEURYSM RUPTURED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENOPIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="125"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="79" subjects_affected="35" subjects_at_risk="125"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="63" subjects_affected="35" subjects_at_risk="125"/>
                <counts group_id="E2" events="31" subjects_affected="17" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="76" subjects_affected="40" subjects_at_risk="125"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="125"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="76" subjects_affected="50" subjects_at_risk="125"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PRURITUS</sub_title>
                <counts group_id="E1" events="61" subjects_affected="45" subjects_at_risk="125"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="166" subjects_affected="97" subjects_at_risk="125"/>
                <counts group_id="E2" events="81" subjects_affected="51" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="171" subjects_affected="87" subjects_at_risk="125"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="157" subjects_affected="77" subjects_at_risk="125"/>
                <counts group_id="E2" events="256" subjects_affected="81" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>TOOTH FRACTURE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ALPHA 1 FOETOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="58" subjects_affected="47" subjects_at_risk="125"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BASOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="42" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="27" subjects_affected="17" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="125"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="125"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>EOSINOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="52" subjects_affected="32" subjects_at_risk="125"/>
                <counts group_id="E2" events="53" subjects_affected="32" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" events="60" subjects_affected="40" subjects_at_risk="125"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="52" subjects_affected="41" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HYALURONIC ACID INCREASED</sub_title>
                <counts group_id="E1" events="90" subjects_affected="62" subjects_at_risk="125"/>
                <counts group_id="E2" events="70" subjects_affected="46" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="134" subjects_affected="80" subjects_at_risk="125"/>
                <counts group_id="E2" events="107" subjects_affected="45" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" events="51" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E2" events="69" subjects_affected="34" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MONOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="111" subjects_affected="62" subjects_at_risk="125"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="48" subjects_affected="31" subjects_at_risk="125"/>
                <counts group_id="E2" events="77" subjects_affected="50" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="109" subjects_affected="74" subjects_at_risk="125"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="57" subjects_affected="41" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>TRI-IODOTHYRONINE FREE DECREASED</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="104" subjects_affected="68" subjects_at_risk="125"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="91" subjects_affected="57" subjects_at_risk="125"/>
                <counts group_id="E2" events="30" subjects_affected="22" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="123" subjects_affected="72" subjects_at_risk="125"/>
                <counts group_id="E2" events="41" subjects_affected="31" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="125"/>
                <counts group_id="E2" events="50" subjects_affected="31" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="108" subjects_affected="68" subjects_at_risk="125"/>
                <counts group_id="E2" events="39" subjects_affected="24" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="164" subjects_affected="82" subjects_at_risk="125"/>
                <counts group_id="E2" events="73" subjects_affected="42" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="78" subjects_affected="49" subjects_at_risk="125"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="51" subjects_affected="42" subjects_at_risk="125"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="94" subjects_affected="48" subjects_at_risk="125"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="53" subjects_affected="42" subjects_at_risk="125"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was prematurely discontinued because of low enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp..</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

